A research group recently reported that human adenocarcinomas commonly harbor mutations in the KRAS and MYC proto-oncogenes and in the TP53 tumor suppressor gene, and that these genetic lesions can be regarded as being potentially pro-angiogenic, as they increase the production of vascular endothelial growth factor (VEGF). The gene discussed is VEGFA; the disease is adenocarcinoma.